Loading clinical trials...

Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients | Clinical Trials | Clareo Health

TERMINATED

Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients

Gadobenate Dimeglumine Compared to Gadobutrol for MRI Perfusion Analysis in Brain Tumor Patients

NCT02095353•University of Nebraska

View on ClinicalTrials.gov

Summary

This study will compare the use of two contrast agents to analyze blood flow characteristics of brain tumors.

Detailed Description

This study will compare contrast agents, gadobenate dimeglumine and gadobutrol, for MRI perfusion analysis in brain tumor patients.

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects with brain tumors will be enrolled. These subjects may be newly diagnosed, undergoing treatment or undergoing follow-up. If a subject has undergone surgery or treatment they should have what appears to be residual tumor.

Exclusion Criteria

•Renal failure (GFR \<45). Subjects will be screened utilizing UNMC gadolinium contrast guidelines.
•Allergic reactions to MRI contrast agents.
•Subjects who do not fit the criteria for the population we are evaluating.
•Subjects should not participate in this study if they have any of the following conditions:
•* Anxiety attacks
•* Panic disorder
•* Claustrophobia
•* Pregnant, or trying to become pregnant
•* Breast feeding
•Subjects should not participate in this study if they have certain kinds of metal in their body, for example: a heart pacemaker, defibrillator, neurostimulator, a metal plate, certain otologic implants, certain types of heart valves, metal slivers in eye, brain aneurysm clips or metal slivers and bullet fragments in or near certain structures in their body. Our standard MRI safety screening will be performed on all subjects.
+1 more criteria

Locations (1)

Unversity of Nebraska Medical Center

Omaha, Nebraska, United States

Key Dates

Start Date

September 1, 2014

Primary Completion Date

March 7, 2017

Completion Date

March 7, 2017

Last Updated

August 23, 2023

Enrollment

ACTUAL participants

Conditions

Central Nervous System Neoplasms

Biomarker Analysis of Central Nervous System Tumors

NCT02692898

Central Nervous System NeoplasmsPrimary Brain Neoplasms+3 more

View study

COMPLETEDPHASE1

Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis

NCT00185848

Brain CancerArthritis, Rheumatoid+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 23, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients

Inclusion Criteria

Exclusion Criteria

Biomarker Analysis of Central Nervous System Tumors

Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis

Coproporphyrine Isomers and Methotrexate Elimination